Could amino acids boost liver cancer treatment?

NCT ID NCT07412054

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding branched-chain amino acids (BCAAs) to the drugs lenvatinib and pembrolizumab helps adults with unresectable liver cancer live longer without their cancer worsening. About 234 participants will be randomly assigned to receive the standard two-drug combination with or without BCAAs. The study will track tumor response, side effects, and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenvatinib, pembrolizumab, and branched-chain amino acids
What this could lead to: If it works, this could point toward a more effective treatment for unresectable liver cancer by adding a simple nutritional supplement to standard therapy.
What could go wrong: This is an early phase 2 trial with a moderate number of participants, so results may not confirm benefit. Adding amino acids could also cause unexpected side effects or no improvement over the current regimen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.